Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.34 |
| ▸ | PNP | P00491 | 2/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2113438 | 0.80 | GDA (0.35) | GDAFGFR1FGFR2PNPFGFR3 | |
| SCHEMBL5133744 | 0.75 | XDH (0.39) | GDAFGFR1FGFR2PNPFGFR3 | |
| SCHEMBL65614 | 0.73 | GDA (0.40) | GDAFGFR1FGFR2PNPFGFR3 | |
| SCHEMBL16513137 | 0.71 | GDA (0.64) | GDAFGFR1FGFR2FGFR3 | |
| SCHEMBL6270959 | 0.68 | FYN (0.52) | — | |
| SCHEMBL6356976 | 0.68 | PNP (0.70) | PNPXDH | |
| SCHEMBL4384740 | 0.67 | XDH (0.67) | PNPXDH | |
| SCHEMBL8547624 | 0.64 | MAT2A (0.31) | PNP | |
| SCHEMBL16513131 | 0.62 | PNP (0.41) | FGFR1FGFR2PNPXDH | |
| SCHEMBL3512361 | 0.62 | XDH (0.55) | GDAXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020169140-A1 | Combination therapy for reduction of toxicity of chemotherapeutic agents | HOLLIS-EDEN PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | claimed |
| EP-2109448-B1 | Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin | ENZON PHARMACEUTICALS INC (US) | 2013-09-11 | — | — | EP | disclosed |
| US-20100279408-A1 | POLYMERIC SHORT INTERFERING RNA CONJUGATES | ENZON PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| EP-2120966-A2 | POLYMERIC SHORT INTERFERING RNA CONJUGATES | Enzon Pharmaceuticals, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080193408-A1 | TREATMENT OF RESISTANT OR REFRACTORY CANCERS WITH MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN | ENZON PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| WO-2008070477-A2 | POLYMERIC SHORT INTERFERING RNA CONJUGATES | ENZON PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080027010-A1 | Treatment of refractory cancers using Na+/K+-ATPase inhibitors | BIONAUT PHARMACEUTICALS, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20070105789-A1 | Combinatorial chemotherapy treatment using Na+/K+ ATPase inhibitors | BIONAUT PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105790-A1 | Pancreatic cancer treatment using Na+/K+ ATPase inhibitors | BIONAUT PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20060135468-A1 | Treatment of refractory cancers using NA+/K+ ATPase inhibitors | BIONAUT PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | US | disclosed |
| US-20060135442-A1 | Pancreatic cancer treatment using Na+/K+ ATPase inhibitors | BIONAUT PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | US | disclosed |
| US-20060135441-A1 | Combinatorial chemotherapy treatment using Na+/K+ ATPase inhibitors | BIONAUT PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135468-A1 | Treatment of refractory cancers using NA+/K+ ATPase inhibitors | ATP1A4, ATP1B1, ATP1A2 | GDA 3227/4885FGFR1 2106/4885FGFR2 3820/4885 |
| US-20100279408-A1 | POLYMERIC SHORT INTERFERING RNA CONJUGATES | SNRPE, RNASE1, PHAX | GDA 1382/4885FGFR1 1834/4885FGFR2 1526/4885 |
| US-20080027010-A1 | Treatment of refractory cancers using Na+/K+-ATPase inhibitors | ATP1A4, ATP1A3, ATP1B3 | GDA 3062/4885FGFR1 2872/4885FGFR2 4234/4885 |
| US-20070105789-A1 | Combinatorial chemotherapy treatment using Na+/K+ ATPase inhibitors | ATP1A4, ATP1A3, HIF1AN | GDA 3151/4885FGFR1 2602/4885FGFR2 4156/4885 |
| US-20060135442-A1 | Pancreatic cancer treatment using Na+/K+ ATPase inhibitors | ATP1A4, ATP1B1, ATP1A1 | GDA 3338/4885FGFR1 2921/4885FGFR2 4265/4885 |
| US-20070105790-A1 | Pancreatic cancer treatment using Na+/K+ ATPase inhibitors | ATP1A4, ATP1A3, ATP1A1 | GDA 3344/4885FGFR1 3028/4885FGFR2 4228/4885 |
| US-20060135441-A1 | Combinatorial chemotherapy treatment using Na+/K+ ATPase inhibitors | ATP1A1, HIF1AN, ATP1A4 | GDA 1830/4885FGFR1 2542/4885FGFR2 3797/4885 |
| US-20080193408-A1 | TREATMENT OF RESISTANT OR REFRACTORY CANCERS WITH MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN | TOP2A, FOLR1, TOP1 | GDA 544/4885FGFR1 2598/4885FGFR2 3134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.